MYO on NYSE
MYOMO, INC.
In its 2026 annual report the company says: “We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs.”5 It is headquartered in Cambridge, United States.2
Price unavailable
Last updated Oct 20, 2026.
Overview
Compare with ALPHA PRO TECH LTD, Jin Medical International Ltd. or Sanara MedTech Inc., or pick any stock.
- TickerMYO on NYSE2
- IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies2
- HeadquartersCambridge, United States2
- Incorporated inDE3
- Business address137 Portland Street, 4Th Floor, Boston, Ma 021143
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300G63SSKC2EGLN412
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 38409452
See how the biggest companies compare on our leaderboards
We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. We primarily provide devices directly to patients and bill their insurance com…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
65.7%Gross margin6
-35.2%Operating margin6
-38.1%Net margin6
25.7%Revenue growth, 20256
-136.6%Return on equity6
0.98×Debt to equity6
-$16.3MFree cash flow6
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue34¢$14.0M
- Research and development17¢$6.9M
- Other costs47¢$19.4M
- Income tax1¢$504.5K
Out of $40.9M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $40.9M | $32.6M |
| Cost of revenue | $14.0M | $9.4M |
| Gross profit | $26.9M | $23.2M |
| Research and development | $6.9M | $4.8M |
| Selling, clinical, and marketing | $20.4M | $12.2M |
| General and administrative | $14.0M | $12.4M |
| Total operating expenses | $41.3M | $29.4M |
| Loss from operations | -$14.4M | -$6.2M |
| Other expense (income) | $450.8K | -$388.6K |
| Loss on equity investment | $216.7K | $0 |
| Total other expense (income) | $667.5K | -$388.6K |
| Loss before income taxes | -$15.1M | -$5.8M |
| Income tax expense | $504.5K | $365.6K |
| Net loss | -$15.6M | -$6.2M |
| Basic | 41.9M shares | 37.8M shares |
| Diluted | 41.9M shares | 37.8M shares |
| Basic | -$0.37 | -$0.16 |
| Diluted | -$0.37 | -$0.16 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $14.1M | $24.4M | |
| Short-term investments | $4.3M | $493.0K | |
| Accounts receivable, net | $4.1M | $3.8M | |
| Inventories | $3.1M | $3.2M | |
| Prepaid expenses and other current assets | $1.9M | $933.4K | |
| Total Current Assets | $27.6M | $32.8M | |
| Restricted cash | $575.0K | $375.0K | |
| Equipment, net | $2.2M | $1.3M | |
| Software development costs | $1.6M | $0 | |
| Operating lease assets with right-of-use, net | $6.7M | $7.6M | |
| Other Assets | $21.4K | $164.4K | |
| Total Assets | $38.6M | $42.2M | |
| Accounts payable and accrued expenses | $5.8M | $9.0M | |
| Current operating lease liability | $494.7K | $748.0K | |
| Taxes payable | $813.3K | $318.9K | |
| Deferred revenue | $218.2K | $83.1K | |
| Warrant derivative liability | $999.4K | $0 | |
| Total Current Liabilities | $8.3M | $10.2M | |
| Non-current operating lease liability, net of current portion | $7.7M | $7.4M | |
| Long-term debt, net of discount of $2,954,857 | $11.2M | $0 | |
| Total Liabilities | $27.2M | $17.5M | |
| Commitments and Contingencies - Note 12 | $0 | $0 | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding | $0 | $0 | |
| Common stock par value $0.0001 per share 65,000,000 shares authorized; 38,471,383 and 34,378,297 shares issued as of December 31, 2025 and 2024, respectively, and 38,471,356 and 34,378,270 shares outstanding as of December 31, 2025 and 2024, respectively. | $3.8K | $3.4K | |
| Additional paid-in capital | $129.9M | $127.8M | |
| Accumulated other comprehensive (loss) income | $164.5K | -$14.4K | |
| Accumulated deficit | -$118.7M | -$103.1M | |
| Treasury stock, at cost; 27 shares of common stock | -$6.5K | -$6.5K | |
| Total Stockholders Equity | $11.4M | $24.7M | $9.0M |
| Total Liabilities and Stockholders Equity | $38.6M | $42.2M | |
| Long-term debt, net of discount | $3.0M | $3.0M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 65.0M shares | 65.0M shares | |
| Common stock, shares issued | 38.5M shares | 34.4M shares | |
| Common stock, shares outstanding | 38.5M shares | 34.4M shares | |
| Treasury shares at cost | 27 shares | 27 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $14.1M | $24.4M | |
| Short-term investments | $4.3M | $493.0K | |
| Accounts receivable, net | $4.1M | $3.8M | |
| Inventories | $3.1M | $3.2M | |
| Prepaid expenses and other current assets | $1.9M | $933.4K | |
| Total Current Assets | $27.6M | $32.8M | |
| Restricted cash | $575.0K | $375.0K | |
| Equipment, net | $2.2M | $1.3M | |
| Software development costs | $1.6M | $0 | |
| Operating lease assets with right-of-use, net | $6.7M | $7.6M | |
| Other Assets | $21.4K | $164.4K | |
| Total Assets | $38.6M | $42.2M | |
| Accounts payable and accrued expenses | $5.8M | $9.0M | |
| Current operating lease liability | $494.7K | $748.0K | |
| Taxes payable | $813.3K | $318.9K | |
| Deferred revenue | $218.2K | $83.1K | |
| Warrant derivative liability | $999.4K | $0 | |
| Total Current Liabilities | $8.3M | $10.2M | |
| Non-current operating lease liability, net of current portion | $7.7M | $7.4M | |
| Long-term debt, net of discount of $2,954,857 | $11.2M | $0 | |
| Total Liabilities | $27.2M | $17.5M | |
| Commitments and Contingencies - Note 12 | $0 | $0 | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding | $0 | $0 | |
| Common stock par value $0.0001 per share 65,000,000 shares authorized; 38,471,383 and 34,378,297 shares issued as of December 31, 2025 and 2024, respectively, and 38,471,356 and 34,378,270 shares outstanding as of December 31, 2025 and 2024, respectively. | $3.8K | $3.4K | |
| Additional paid-in capital | $129.9M | $127.8M | |
| Accumulated other comprehensive (loss) income | $164.5K | -$14.4K | |
| Accumulated deficit | -$118.7M | -$103.1M | |
| Treasury stock, at cost; 27 shares of common stock | -$6.5K | -$6.5K | |
| Total Stockholders Equity | $11.4M | $24.7M | $9.0M |
| Total Liabilities and Stockholders Equity | $38.6M | $42.2M | |
| Long-term debt, net of discount | $3.0M | $3.0M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 65.0M shares | 65.0M shares | |
| Common stock, shares issued | 38.5M shares | 34.4M shares | |
| Common stock, shares outstanding | 38.5M shares | 34.4M shares | |
| Treasury shares at cost | 27 shares | 27 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$15.6M | -$6.2M |
| Depreciation | $859.4K | $205.9K |
| Stock-based compensation | $2.1M | $874.4K |
| Accretion of discount on short-term investments | -$43.0K | -$118.6K |
| Credit losses | $158.0K | $43.7K |
| Amortization of final payment fees of old debt | $215.0K | $0 |
| Amortization of right-of-use assets | $905.3K | $571.1K |
| Amortization of deferred offering cost | $520.4K | $41.6K |
| Change in fair value of derivative liabilities | $216.7K | $0 |
| Other non-cash changes, net | $3.8K | $16.0K |
| Accounts receivable | $377.0K | -$1.6M |
| Inventories | -$662.7K | -$1.4M |
| Prepaid expenses and other current assets | -$1.3M | -$887.5K |
| Other assets | $6.5K | $84.8K |
| Accounts payable and accrued expenses | -$2.9M | $4.7M |
| Operating lease liabilities | $54.1K | -$503.5K |
| Deferred revenue | $135.1K | $74.6K |
| Income tax payable | $436.7K | $236.7K |
| Tenant improvement allowance | $0 | $516.3K |
| Net cash used in operating activities | -$14.5M | -$3.3M |
| Purchases of equipment | -$1.7M | -$1.4M |
| Purchases of software development | -$1.6M | $0 |
| Maturities of short-term investments | $1.7M | $7.6M |
| Purchases of short-term investments | -$5.5M | -$6.0M |
| Net cash provided by (used in) investing activities | -$7.1M | $260.0K |
| Deferred debt origination costs | $0 | -$199.5K |
| Proceeds from sale of pre-funded warrants, net of offering costs | $0 | $763.1K |
| Proceeds from sale of common stock and pre-funded warrants, net of offering costs | $0 | $20.4M |
| Repayment of debt | -$4.0M | $0 |
| Final payment fees of old debt | -$215.0K | $0 |
| Payment of debt issuance costs | -$857.6K | $0 |
| Proceeds from issuance of debt, revolving credit line | $1.0M | $0 |
| Proceeds from issuance of debt, term loan | $3.0M | $0 |
| Proceeds from issuance of debt, Avenue Capital | $12.5M | $0 |
| Net cash provided by financing activities | $11.4M | $20.9M |
| Effect of foreign exchange rate changes on cash | $101.7K | -$26.4K |
| Net increase in cash and cash equivalents | -$10.0M | $17.9M |
| Cash paid during the period for income taxes | $330.9K | $0 |
| Cash paid during the period for interest | $111.9K | $0 |
| Right of use assets obtained in exchange for lease obligations | $0 | $7.5M |
| Unrealized (gain) loss from mark to market on short-term investments | $922 | $165 |
No quarter-by-quarter statement was filed.
Corporate structure
MYOMO, INC. sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of MYOMO, INC.
- Rosalind Advisors, Inc. Filed SCHEDULE 13G/A on MYOMO, INC., latest Aug 12, 2026 (14 filings since Jan 20, 2022)
- Horton Capital Partners, LLC Filed SCHEDULE 13D/A on MYOMO, INC., latest May 18, 2026 (2 filings since Dec 29, 2025)
- Orin Hirschman Filed SCHEDULE 13G/A on MYOMO, INC., latest Nov 10, 2025 (8 filings since Oct 6, 2021)
- Triple Gate Partners, LP Filed SC 13G/A on MYOMO, INC., latest Jun 4, 2024 (2 filings since Aug 31, 2023)
- Paul Packer Filed SC 13G/A on MYOMO, INC., latest Feb 14, 2024 (2 filings since Jan 20, 2023)
- Strategic Risk, LLC. Filed SC 13G on MYOMO, INC., latest Mar 28, 2023
- Hewlett Fund LP Filed SC 13G/A on MYOMO, INC., latest Feb 15, 2023 (2 filings since Jan 17, 2023)
- Must Asset Management Inc. Filed SC 13G/A on MYOMO, INC., latest Feb 7, 2023 (2 filings since May 18, 2022)
- MYOMO, INC. Cambridge, Massachusetts, United States
- Myomo Europe GmbH Subsidiary · Germany
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What MYOMO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $4.1M6 Dec 31, 2025 | $2.3M6 Dec 31, 2024 | +74.9% |
| Accumulated depreciation | $1.9M6 Dec 31, 2025 | $994.9K6 Dec 31, 2024 | +86.4% |
| Property and equipment, net | $2.2M6 Dec 31, 2025 | $1.3M6 Dec 31, 2024 | +66.4% |
| Operating-lease assets (leased space) | $6.7M6 Dec 31, 2025 | $7.6M6 Dec 31, 2024 | −11.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $14.1M6 Dec 31, 2025 | $24.4M6 Dec 31, 2024 | −42.0% |
| Marketable securities, current | $4.3M6 Dec 31, 2025 | $493.0K6 Dec 31, 2024 | +764.5% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $3.1M6 Dec 31, 2025 | $3.2M6 Dec 31, 2024 | −1.4% |
| Work in process | $28.2K6 Dec 31, 2025 | $60.7K6 Dec 31, 2024 | −53.6% |
| Finished goods | $930.8K6 Dec 31, 2025 | $1.3M6 Dec 31, 2024 | −27.8% |
Properties, in its own words
Our primary offices are located at 45 Blue Sky Drive in Burlington, Massachusetts, where we have a lease expiring in October 2032 consisting of approximately 36,200 square feet of office, manufacturing and laboratory space. We believe our facilities are currently adequate for us to conduct our business. A number of our employees work remotely from home across the United States and Germany.
Item 2 of the 10-K filed Mar 9, 2026.5
Leadership
Who has led MYOMO, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
20202025
- Chief executive officerPaul R. Gudonis Jun 12, 2017 to now14
- Chief financial officerDavid A. Henry Feb 20, 2019 to now15
- Chief financial officerRalph A. Goldwasser Jun 12, 2017 to Jan 24, 201916
Board members and other officers (16)
- Chief Medical OfficerHarry Kovelman Mar 25, 2021 to now17
- Chief Commercial OfficerMicah Mitchell Jul 11, 2018 to now18
- VP, SALES & CLINICAL SERVICESDavie Mendelsohn Jun 12, 2017 to Jan 24, 201919
- VICE PRESIDENT, GMJonathan Naft Jun 12, 2017 to Jul 6, 202020
- Chief Medical OfficerBrandon M. Green Aug 30, 2017 to Jun 8, 202021
- Chief Marketing OfficerCliff Conneighton Sep 13, 2017 to Jun 14, 202122
- Board memberWilliam J. Febbo Apr 16, 2026 to now23
- Board memberJoseph M. Manko Jr. May 18, 2026 to now24
- Board memberHeather C. Getz Mar 28, 2024 to now25
- Board memberYitzchak Jacobovitz Feb 24, 2023 to Feb 24, 202326
- Board memberMilton Mayo Morris Jun 21, 2021 to now27
- Board memberAmy K. Knapp Jun 12, 2017 to Jun 7, 202428
- Board memberPaul R. Gudonis Jun 12, 2017 to now14
- Board memberSteve Sanghi Jun 12, 2017 to Nov 27, 201929
- Board memberThomas Aloysius Crowley Jr. Jun 12, 2017 to now30
- Board memberThomas F. Kirk Jun 12, 2017 to now31
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Myomo Europe GmbH Germany4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- MYOMO INCJun 30, 2006 to Feb 24, 20203
Timeline
- Aug 5, 20268-K Results of operations32
- Jun 29, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote33
- Jun 26, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote34
- May 13, 20268-K Executive or director change; Regulation FD disclosure35
- May 7, 20268-K Results of operations36
- Apr 16, 20268-K Executive or director change; Regulation FD disclosure37
- Mar 9, 20268-K Results of operations38
- Dec 16, 20258-K Executive or director change39
- Nov 10, 20258-K Entered a material agreement; Results of operations; New debt or obligation40
- Aug 11, 20258-K Results of operations41
- Jun 18, 20258-K Regulation FD disclosure42
- Jun 13, 20258-K Shareholder vote43
- Jun 12, 2017New chief executive Paul R. Gudonis becomes CEO14
- Sep 1, 2004Founded MYOMO, INC. is founded2
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.09) a share, on Nov 10, 2025.44
When it reported results
- Aug 5, 2026Reported quarterly or annual results32
- May 7, 2026Reported quarterly or annual results36
- Mar 9, 2026Reported quarterly or annual results38
- Nov 10, 2025Reported quarterly or annual results40
- Aug 11, 2025Reported quarterly or annual results41
- May 7, 2025Reported quarterly or annual results45
- Mar 10, 2025Reported quarterly or annual results46
- Nov 6, 2024Reported quarterly or annual results47
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
412 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 60 major events, 195 insider forms, 33 large holders, 103 other. The latest 20:
- Oct 15, 20264 EDGAR
- Oct 15, 20264/A EDGAR
- Oct 15, 20264 EDGAR
- Oct 15, 20264 EDGAR
- Oct 13, 20264 EDGAR
- Oct 13, 20264 EDGAR
- Oct 13, 2026144 EDGAR
- Oct 13, 20264 EDGAR
- Oct 13, 20263 EDGAR
- Oct 13, 2026S-8 EDGAR
- Sep 14, 20264 EDGAR
- Sep 11, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Aug 24, 20264/A EDGAR
- Aug 21, 20264 EDGAR
- Aug 20, 2026144 EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 20264 EDGAR
- Aug 11, 20264 EDGAR
The 412 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
62 open-market trades by officers, directors and large owners since October 2021: 38 buys and 24 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Kovelman HarryChief Medical Officer | Sale | 15,488 | $1.27 | $19.7K | Form 4 |
| Sep 2, 2026 | Morris Milton MayoDirector | Sale | 15,000 | $1.41 | $21.1K | Form 4 |
| Aug 20, 2026 | Kovelman HarryChief Medical Officer | Sale | 17,500 | $1.73 | $30.3K | Form 4 |
| Aug 20, 2026 | Kovelman HarryChief Medical Officer | Sale | 17,250 | $1.73 | $29.8K | Form 4 |
| Jun 5, 2026 | KIRK THOMAS FDirector | Buy | 40,002 | $1.27 | $50.8K | Form 4 |
| May 28, 2026 | KIRK THOMAS FDirector | Buy | 25,000 | $0.99 | $24.8K | Form 4 |
| May 28, 2026 | Kovelman HarryChief Medical Officer | Sale | 11,536 | $1.02 | $11.8K | Form 4 |
| May 27, 2026 | Kovelman HarryChief Medical Officer | Sale | 20,464 | $1.00 | $20.5K | Form 4 |
| May 18, 2026 | KIRK THOMAS FDirector | Buy | 43,401 | $0.91 | $39.5K | Form 4 |
| May 15, 2026 | Manko Joseph M. Jr.Director | Buy | 30,367 | $0.89 | $27.0K | Form 4 |
| May 15, 2026 | KIRK THOMAS FDirector | Buy | 31,605 | $0.91 | $28.8K | Form 4 |
| May 14, 2026 | Manko Joseph M. Jr.Director | Buy | 170,830 | $0.86 | $146.9K | Form 4 |
| May 14, 2026 | Mitchell MicahChief Commercial Officer | Sale | 90,231 | $0.86 | $77.6K | Form 4 |
| Mar 16, 2026 | Getz Heather CDirector | Buy | 20,000 | $0.70 | $14.0K | Form 4 |
| Mar 13, 2026 | KIRK THOMAS FDirector | Buy | 72,000 | $0.71 | $51.1K | Form 4 |
| Mar 12, 2026 | Getz Heather CDirector | Buy | 70,000 | $0.73 | $51.1K | Form 4 |
| Nov 21, 2025 | KIRK THOMAS FDirector | Buy | 2,535 | $0.72 | $1.8K | Form 4 |
| Nov 20, 2025 | KIRK THOMAS FDirector | Buy | 4,902 | $0.72 | $3.5K | Form 4 |
| Nov 19, 2025 | Crowley Thomas Aloysius Jr.Director | Buy | 385 | $0.77 | $296 | Form 4 |
| Nov 18, 2025 | Crowley Thomas Aloysius Jr.Director | Buy | 4,000 | $0.73 | $2.9K | Form 4 |
All 62 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Rosalind Advisors, Inc.SCHEDULE 13G/A, 14 filings Jan 20, 2022 to Aug 12, 202648
- Horton Capital Partners, LLCSCHEDULE 13D/A, 2 filings Dec 29, 2025 to May 18, 202649
- Orin HirschmanSCHEDULE 13G/A, 8 filings Oct 6, 2021 to Nov 10, 202550
- Triple Gate Partners, LPSC 13G/A, 2 filings Aug 31, 2023 to Jun 4, 202451
- Paul PackerSC 13G/A, 2 filings Jan 20, 2023 to Feb 14, 202452
- Strategic Risk, LLC.SC 13G, 1 filing Mar 28, 202353
- Hewlett Fund LPSC 13G/A, 2 filings Jan 17, 2023 to Feb 15, 202354
- Must Asset Management Inc.SC 13G/A, 2 filings May 18, 2022 to Feb 7, 202355
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Paul R. Gudonis, | 72 | $375.0K | $1.2M56 |
| 2025 | David A. Henry | 64 | $283.9K | $690.2K56 |
| 2025 | Harry Kovelman, | 67 | $283.7K | $607.8K56 |
| 2024 | Chief Executive Officer | $348.1K | $1.2M56 | |
| 2024 | Chief Financial Officer | $263.6K | $784.2K56 | |
| 2024 | Chief Medical Officer | $273.7K | $695.1K56 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 80. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,637,886 | $3.8M | 1.4% | −209,386 |
| Vanguard Capital Management LLC | 1,636,570 | $1.7M | 0.0% | +492,246 |
| Aqr Capital Management LLC | 928,268 | $965.4K | 0.0% | +609,317 |
| Jefferies Financial Group Inc. | 704,275 | $732.4K | 0.0% | No change |
| Jane Street Group, LLC | 596,352 | $620.2K | 0.0% | New |
| Clearstead Advisors, LLC | 425,609 | $442.6K | 0.0% | +9 |
| UBS Group AG | 413,679 | $430.2K | 0.0% | +101,958 |
| Geode Capital Management, LLC | 344,417 | $358.3K | 0.0% | −514,382 |
| LPL Financial LLC | 308,000 | $320.3K | 0.0% | +2,000 |
| Palumbo Wealth Management LLC | 299,776 | $311.8K | 0.1% | New |
| Millennium Management LLC | 271,294 | $282.1K | 0.0% | New |
| BlackRock, Inc. | 223,217 | $232.1K | 0.0% | −1,465,173 |
| Vanguard Fiduciary Trust Co | 207,677 | $216.0K | 0.0% | −29,575 |
| Bnp Paribas Financial Markets | 139,194 | $144.8K | 0.0% | +131,048 |
| Ieq Capital, LLC | 127,749 | $132.9K | 0.0% | +93,910 |
| Susquehanna International Group, Llp | 120,791 | $125.6K | 0.0% | +82,402 |
| XTX Topco Ltd | 110,028 | $114.4K | 0.0% | +6,933 |
| State Street Corp | 105,875 | $110.1K | 0.0% | −277,316 |
| Citadel Advisors LLC | 102,518 | $106.6K | 0.0% | New |
| Goldman Sachs Group Inc | 94,848 | $98.6K | 0.0% | −74,097 |
| Centiva Capital, LP | 85,996 | $89.4K | 0.0% | New |
| Northern Trust Corp | 80,609 | $83.8K | 0.0% | −133,438 |
| Qube Research & Technologies Ltd | 67,764 | $70.5K | 0.0% | New |
| Stratos Wealth Partners, LTD. | 60,000 | $62.4K | 0.0% | No change |
| Renaissance Technologies LLC | 48,500 | $50.4K | 0.0% | +24,900 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How MYOMO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARMYOMO, INC.1
- CIK0001369290
- Employer ID (EIN)47-09445265
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address137 Portland Street, 4Th Floor, Boston, MA 021141
- Phone617-996-90581
- Shares outstanding39,607,854 as of Jul 31, 202613
- Public float$62.4M as of Jun 30, 20255
- AuditorCBIZ, LLP, New York, NY, USA PCAOB ID 199; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceJun 30, 20061
- Filings693 in all: 4 (251), 8-K (111), 144 (57), 10-Q (28), SC 13G/A (26), 3 (20), 4/A (18), SC 13G (17)1
All 48 form types
CORRESP (16), 424B5 (12), S-1/A (12), DEF 14A (11), S-8 (11), DEFA14A (10), UPLOAD (10), 10-K (9), SCHEDULE 13G/A (8), EFFECT (6), D (5), ARS (4), PRE 14A (4), 1-A/A (3), 424B4 (3), FWP (3), S-1 (3), S-1MEF (3), S-3 (3), SD (3), 1-A POS (2), 8-K/A (2), CT ORDER (2), POS EX (2), QUALIF (2), REGDEX (2), 1-A (1), 10-K/A (1), 253G2 (1), 253G4 (1), 5 (1), 8-A12B (1), CERTNAS (1), D/A (1), DOS (1), DRS (1), REGDEX/A (1), S-3/A (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 9, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) May 14, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value per share | MYO | NYSE American |
From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks MYOMO, INC. names in Item 1A of its 10-K filed Mar 9, 2026: 56 risks under these headings, as written.5
- making an investment decision. The risks described below are not the only ones we face. Additional risks not presently known to us or that we currently believe are not material may also significantly impair our business operations. Our business could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and investors may lose all or part of their investment.
- Risks Associated with Our Business
- Risks Related to Our Operating and Financial Results
- We have a history of operating losses. Investments in advertising, R&D and clinical, reimbursement and manufacturing capacity could result in a delay in our ability to achieve cash flow breakeven on a quarterly basis.
- Our direct billing revenues are concentrated with a small number of payers, including CMS. Adverse changes in the reimbursement policies of these payers regarding the MyoPro could have an adverse effect on our business.
- We may experience significant fluctuations in our quarterly and annual results.
- Continued inflation may materially impact our financial operations or results of operations.
- Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.
- Risks related to our Reliance on Third Parties
- We may not be able to obtain third-party payer reimbursement, including reimbursement by Medicare, for our products.
- If CMS amends, restricts, or retracts coverage requirements, its billing contractors and insurers offering Medicare Advantage insurance plans may restrict what they reimburse for the MyoPro, which would have an adverse effect on our business.
- Changes made by direct to consumer advertising platforms (such as social media) in how they reach prospective patients could adversely impact our lead generation efforts, resulting in higher advertising cost per addition to our patient pipeline and have an adverse effect on revenues.
The other 47 risks
- We currently rely, and in the future will rely, on sales of our MyoPro products for our revenue, and we may not be able to expand market acceptance or grow revenues in the orthotics and prosthetics channel.
- We depend on a single third-party to manufacture key subassemblies for the MyoPro and a limited number of third-party suppliers for certain components of the MyoPro.
- Risks Related to Capital Requirements
- We may not have sufficient funds to meet our future capital requirements.
- The terms of our Loan and Security Agreement with Avenue require us to meet certain operating covenants and place restrictions on our operating and financial flexibility. Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.
- If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
- Risks Related to Competitors and Our Market
- The industries in which we operate are highly competitive and subject to rapid technological change. The publishing of fees for the HCPCS billing codes for our products may attract competition. If our competitors are better able to develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may be unable to compete effectively with other companies.
- We sell to O&P providers who are free to market products that compete with the MyoPro, and we rely on these providers to market and promote our products in accordance with their FDA listings, select appropriate patients and provide adequate follow-on care.
- The market for myoelectric braces is relatively new and the rate of adoption is uncertain, and important assumptions about the potential market for our products may be inaccurate.
- Risks Related to Our Products
- We may receive a significant number of warranty claims or our MyoPro may require significant amounts of service after sale.
- Defects in our products or the software that drives them could adversely affect the results of our operations.
- While there is long-term clinical data supporting the safety of our existing MyoPro products, updates to our products inherently have uncertain safety risks as they enter the market.
- Risks Related to Collaborations and Licensing Agreements
- We may enter into collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues.
- Risks Related to Our Business Operations and Management
- If we fail to properly manage our anticipated growth, including in O&P channel and international markets, our business could suffer.
- We depend on the knowledge and skills of our senior management.
- We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could have a material adverse effect on our business, financial condition and operating results.
- Risks Related to Government Regulation
- Risks Related to Healthcare Industry
- We are subject to extensive governmental regulations relating to the design, development, manufacturing, labeling, marketing, delivery and billing of our products, and a failure to comply with such regulations could lead to withdrawal or recall of our products from the market.
- Our relationships with healthcare providers and physicians and third-party payers are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- If we or our third-party manufacturers or key suppliers fail to comply with the applicable good manufacturing practice requirements, including FDA’s Quality Management System Regulation, our manufacturing operations could be interrupted.
- Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- We face risks in connection with the Affordable Care Act (“ACA”) or its possible replacement or modifications and other ongoing healthcare legislative and regulatory reform measures.
- Risks Related to Cybersecurity and Data Protection
- Our internal computer systems, or those of our customers, collaborators or other contractors, third-party service providers and vendors may be subject to cyber-attacks, compromises or security incidents, which could result in a material disruption of our product development programs.
- We, our collaborators and our service providers may be subject to a variety of privacy and data protection laws, regulations and contractual obligations, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with them could expose us to fines or other penalties and otherwise harm our business and operations.
- European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.
- Issues relating to the use of artificial intelligence and machine learning could adversely affect our business and operating results.
- Risks Related to Our Intellectual Property
- Our success depends in part on our ability to obtain and maintain protection for the intellectual property relating to or incorporated into our products.
- We are not able to protect our intellectual property rights in all countries.
- We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our current and future products.
- We rely on trademark protection to distinguish our products from the products of our competitors.
- We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.
- Risks Related to our Securities
- Risks Related to Ownership of Our Securities
- Our stockholders will experience significant dilution upon the issuance of common stock if the shares of our common stock underlying our warrants are exercised or converted or if Avenue elects to convert some principal payments into common stock.
- We may not be able to maintain a listing of our common stock on the NYSE American.
- Actions of activist stockholders could be disruptive and costly and could adversely affect our results of operations, financial condition, and/or share price
- There is no public market for our warrants or pre-funded warrants to purchase common stock.
- Holders of our warrants and pre-funded warrants have no rights as a common stockholder until such holders exercise their warrants and acquire our common stock.
- The market price of our common stock has been and may continue to be volatile.
- We do not expect to declare or pay dividends in the foreseeable future.
- If securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our common stock could be negatively affected.
- Future issuances of our common stock or equity-related securities could cause the market price of our common stock to decline and would result in the dilution of your holdings.
- Future issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely affect our common stock price.
- If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.
- Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.
- Risks Related to Internal Controls
- We are a "smaller reporting company” under the reporting rules set forth under the Exchange Act. For so long as we remain a “smaller reporting company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not “smaller reporting companies”.
- We are obligated to develop and maintain a system of effective internal control over financial reporting. We may not complete our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may harm investor confidence in our company and, as a result, the value of our common stock.
- The preparation of our financial statements involves the use of estimates, judgments and assumptions, and our financial statements may be materially affected if such estimates, judgments or assumptions prove to be inaccurate.
- We are incurring increased costs as a public company and our management team is required to devote substantial time to new compliance initiatives and corporate governance practices.
- Risks Related to Tax Laws
- We may be subject to adverse legislative or regulatory changes in tax laws that could negatively impact our financial condition.
- Our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations.
Legal proceedings
The Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There is no material litigation against the Company at this time that is required to be disclosed under Item 103 of Regulation S-K.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARMYOMO, INC. filings on SEC EDGAR
- 2
- 3SEC EDGARMYOMO, INC. filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARMYOMO, INC. 10-K for fiscal 2025
- 7SEC EDGARMYOMO, INC. 10-K for fiscal 2019
- 8SEC EDGARMYOMO, INC. 10-K for fiscal 2020
- 9SEC EDGARMYOMO, INC. 10-K for fiscal 2021
- 10SEC EDGARMYOMO, INC. 10-K for fiscal 2022
- 11SEC EDGARMYOMO, INC. 10-K for fiscal 2023
- 12SEC EDGARMYOMO, INC. 10-Q for fiscal 2026
- 13SEC EDGARMYOMO, INC. 10-Q for fiscal 2026
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARJonathan Naft, VICE PRESIDENT, GM
- 21
- 22
- 23SEC EDGARWilliam J. Febbo, Board member
- 24SEC EDGARJoseph M. Manko Jr., Board member
- 25SEC EDGARHeather C. Getz, Board member
- 26SEC EDGARYitzchak Jacobovitz, Board member
- 27SEC EDGARMilton Mayo Morris, Board member
- 28SEC EDGARAmy K. Knapp, Board member
- 29SEC EDGARSteve Sanghi, Board member
- 30
- 31SEC EDGARThomas F. Kirk, Board member
- 32SEC EDGARResults of operations
- 33
- 34
- 35
- 36SEC EDGARResults of operations
- 37
- 38SEC EDGARResults of operations
- 39SEC EDGARExecutive or director change
- 40
- 41SEC EDGARResults of operations
- 42SEC EDGARRegulation FD disclosure
- 43SEC EDGARShareholder vote
- 44NasdaqNasdaq calendar
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52SEC EDGARPaul Packer SC 13G/A on MYOMO, INC.
- 53
- 54
- 55
- 56